放化疗模式及同步化疗周期数对局限期小细胞肺癌疗效及预后的影响  

Influence of chemoradiotherapy mode and number of synchronized chemotherapy cycles on efficacy and prognosis of limited-stage small cell lung cancer

作　　者：常春禹 刘阳 曲皎月 汪庚明 CHANG Chunyu;LIU Yang;QU Jiaoyue;WANG Gengming(Department of Tumor Radiotherapy,First Affiliated Hospital of Bengbu Medical University,Bengbu,Anhui 233000,China)

机构地区：[1]蚌埠医科大学第一附属医院肿瘤放疗科,安徽蚌埠233000

出　　处：《重庆医学》2025年第2期360-365,371,共7页Chongqing Medical Journal

基　　金：安徽省临床医学优先发展重点专科项目(卫科教秘2018-291号);2020年度蚌埠医学院第一附属医院一般新技术项目(2020123)。

摘　　要：目的 探讨放化疗模式及同步化疗周期数对局限期小细胞肺癌(LS-SCLC)患者的疗效及总生存(OS)时间的影响。方法 回顾性分析2018年1月至2022年12月于该院肿瘤放疗科接受胸部放疗的85例LS-SCLC患者的临床资料,根据不同的放化疗模式分为同步化疗组(n=43)和无同步化疗组(n=42)。比较两组OS和无进展生存(PFS)时间,并分析LS-SCLC预后的相关影响因素。结果 末次随访日期为2023年11月1日,全组中位随访时间为39.6个月。同步化疗组与无同步化疗组中位OS时间分别为30.6、18.6个月,差异有统计学意义(P<0.05)。同步化疗组中1个周期与2个周期的中位OS时间分别为25.5、33.6个月,差异无统计学意义(P>0.05)。Cox多因素回归分析结果显示,年龄、临床分期和预防性脑照射(PCI)是LS-SCLC患者预后的独立影响因素(P<0.05)。结论 同步化疗周期数对LS-SCLC的预后无明显影响。Objective To explore the influence of the radiochemotherapy mode and the number of synchronized chemotherapy cycles on the efficacy and overall survival(OS)time of the patients with limited-stage small cell lung cancer(LS-SCLC).Methods The clinical data of 85 patients with LS-SCLC receiving the thoracic radiotherapy(TRT)in the tumor radiotherapy department of this hospital from January 2018 to December 2022 were retrospectively analyzed.The patients were divided into the synchronous chemotherapy group(n=43)and non-synchronous chemotherapy group(n=42)according to different radiochemotherapy modes.The OS and progress free survival(PFS)time was compared between the two groups,and the related prognostic influencing factors of LS-SCLC were analyzed.Results The last follow-up date was November 1,2023,and the median follow-up time in all groups was 39.6 months.The median OS time of the synchronous chemotherapy group and non-synchronous chemotherapy group was 30.6 months and 18.6 months respectively,and the difference was statistically significant(P<0.05).The median OS time of 1 cycle and 2 cycles in the synchronous chemotherapy group was 25.5 months and 33.6 months,and the difference was not statistically significant(P>0.05).The Cox multivariate regression analysis results showed that the age,clinical stage and prophylactic cranial irradiation(PCI)were the independent prognostic influencing factors in the patients with LS-SCLC.Conclusion The number of synchronized chemotherapy cycles has no significant influence on the prognosis of LS-SCLC.

关 键 词：小细胞肺癌 局限期 同步放化疗 总生存时间 预后因素 

分 类 号：R734.2[医药卫生—肿瘤]